Ironwood Pharmaceuticals Stock Analysis

IRWD Stock  USD 6.63  0.19  2.79%   
Ironwood Pharmaceuticals is undervalued with Real Value of 8.81 and Target Price of 16.5. The main objective of Ironwood Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Ironwood Pharmaceuticals is worth, separate from its market price. There are two main types of Ironwood Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Ironwood Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ironwood Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

Ironwood Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 6.78. Ironwood Pharmaceuticals last dividend was issued on the 2nd of April 1970. The entity had 1194:1000 split on the 2nd of April 2019. Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 219 people. To learn more about Ironwood Pharmaceuticals call the company at 617 621 7722 or check out

Ironwood Pharmaceuticals Quarterly Total Revenue

74.88 Million

Ironwood Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ironwood Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ironwood Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ironwood Pharmaceuticals generated a negative expected return over the last 90 days
Ironwood Pharmaceuticals has high historical volatility and very poor performance
Ironwood Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 442.74 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 366.33 M.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from Implied Volatility Surging for Ironwood Pharmaceuticals Stock Options

Ironwood Pharmaceuticals Upcoming and Recent Events

15th of February 2024
Upcoming Quarterly Report
2nd of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
15th of February 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Ironwood Largest EPS Surprises

Earnings surprises can significantly impact Ironwood Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Ironwood Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Ironwood Pharmaceuticals' ESG score is a quantitative measure that evaluates Ironwood Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Ironwood Pharmaceuticals' operations that may have significant financial implications and affect Ironwood Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Ironwood Pharmaceuticals Thematic Classifications

In addition to having Ironwood Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Obamacare Repeal Idea
Obamacare Repeal
Large healthcare related equities associated with Obamacare

Ironwood Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Man Group Plc2024-03-31
Brown Capital Management, Llc2024-03-31
2.7 M
Morgan Stanley - Brokerage Accounts2024-03-31
2.7 M
Nuveen Asset Management, Llc2024-03-31
1.8 M
Kynam Capital Management, Lp2024-03-31
1.6 M
Northern Trust Corp2024-03-31
1.5 M
Deutsche Bank Ag2024-03-31
1.5 M
Jupiter Asset Management Limited2024-03-31
1.5 M
Charles Schwab Investment Management Inc2024-03-31
1.4 M
Blackrock Inc2024-03-31
24.2 M
Vanguard Group Inc2024-03-31
19.5 M
Note, although Ironwood Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ironwood Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.05 B.

Ironwood Profitablity

The company has Profit Margin (PM) of (2.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15.
Last ReportedProjected for Next Year
Return On Tangible Assets(2.14)(2.04)
Return On Capital Employed 1.07  1.13 
Return On Assets(2.13)(2.02)
Return On Equity 2.89  3.04 

Management Efficiency

Ironwood Pharmaceuticals has return on total asset (ROA) of 0.1154 % which means that it generated a profit of $0.1154 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7472) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.
Last ReportedProjected for Next Year
Book Value Per Share(2.23)(2.34)
Tangible Book Value Per Share(2.25)(2.36)
Enterprise Value Over EBITDA 11.40  11.97 
Price Book Value Ratio(5.13)(4.88)
Enterprise Value Multiple 11.40  11.97 
Price Fair Value(5.13)(4.88)
Enterprise Value2.2 B2.4 B
The analysis of Ironwood Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Ironwood Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Ironwood Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin
Profit Margin
Return On Assets
Return On Equity

Technical Drivers

As of the 19th of July, Ironwood Pharmaceuticals retains the Risk Adjusted Performance of (0.02), standard deviation of 4.03, and Market Risk Adjusted Performance of (0.16). Ironwood Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Ironwood Pharmaceuticals information ratio and skewness to decide if Ironwood Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 6.63 per share. Given that Ironwood Pharmaceuticals has information ratio of (0.07), we strongly advise you to confirm Ironwood Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.

Ironwood Pharmaceuticals Price Movement Analysis

Time Period
Deviations up
Deviations down
MA Type
Execute Study
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ironwood Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ironwood Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Ironwood Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ironwood Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ironwood Pharmaceuticals Outstanding Bonds

Ironwood Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ironwood Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ironwood bonds can be classified according to their maturity, which is the date when Ironwood Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Ironwood Pharmaceuticals Predictive Daily Indicators

Ironwood Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ironwood Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ironwood Pharmaceuticals Corporate Filings

21st of June 2024
Report filed with the SEC to announce major events that shareholders should know about
20th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
18th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
12th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
10th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
22nd of May 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
20th of May 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
9th of May 2024
Report filed with the SEC to announce major events that shareholders should know about

Ironwood Pharmaceuticals Forecast Models

Ironwood Pharmaceuticals' time-series forecasting models are one of many Ironwood Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ironwood Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Ironwood Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ironwood Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ironwood shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ironwood Pharmaceuticals. By using and applying Ironwood Stock analysis, traders can create a robust methodology for identifying Ironwood entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(2.14)(2.25)
Operating Profit Margin 0.47  0.50 
Net Loss(2.26)(2.38)
Gross Profit Margin 1.00  0.74 

Current Ironwood Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ironwood analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ironwood analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
16.5Strong Buy6Odds
Ironwood Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ironwood analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ironwood stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ironwood Pharmaceuticals, talking to its executives and customers, or listening to Ironwood conference calls.
Ironwood Analyst Advice Details

Ironwood Stock Analysis Indicators

Ironwood Pharmaceuticals stock analysis indicators help investors evaluate how Ironwood Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ironwood Pharmaceuticals shares will generate the highest return on investment. By understating and applying Ironwood Pharmaceuticals stock analysis, traders can identify Ironwood Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow657.5 M
Long Term Debt498.3 M
Common Stock Shares Outstanding155.4 M
Total Stockholder Equity-346.3 M
Tax Provision74.8 M
Quarterly Earnings Growth Y O Y-0.685
Property Plant And Equipment Net18.2 M
Cash And Short Term Investments92.2 M
Cash92.2 M
Accounts Payable7.8 M
Net Debt623.4 M
50 Day M A6.4344
Total Current Liabilities276.1 M
Other Operating Expenses233.7 M
Non Current Assets Total237.8 M
Forward Price Earnings12.3305
Non Currrent Assets Other3.6 M
Stock Based Compensation32 M

Complementary Tools for Ironwood Stock analysis

When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios